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Hepatectomy for rapidly growing solitary
liver metastasis from non-small cell lung
cancer: a case report
Hiroyuki Hakoda1, Yasuharu Sekine2, Hideo Ichimura2,4,5* , Kazumitsu Ueda1, Shigeo Aoki1, Hideyuki Mishima1,
Akihiro Sako1, Keisuke Kobayashi2, Akiko Sakata3 and Yukio Sato4
Abstract
Background: Patients with liver metastasis from non-small lung cancer (NSCLC) usually have multiple metastases at
other sites and thus rarely undergo liver surgery. We present a case involving successful resection of rapidly
growing liver metastasis from squamous cell carcinoma of the lung.
Case presentation: A 74-year-old man had undergone left lower lobectomy for squamous cell carcinoma of the
lung, which was diagnosed pathologically as stage IA. A computed tomography (CT) scan that was taken 12
months after lung resection showed an irregularly shaped mass lesion (size, 8.3 cm) in segment five of the liver.
Retrospectively, the mass was identifiable on CT 6 months before this initial recognition. Although the lesion
showed rapid growth, positron emission tomography and brain magnetic resonance imaging ruled out the
possibility of other metastatic lesions. Therefore, we performed right hepatectomy 14 months after the initial lung
surgery. The patient was pathologically diagnosed with liver metastasis from lung cancer and has remained free
from recurrence 41 months after the liver surgery, without receiving any adjuvant chemotherapy.
Conclusions: Although there is no reliable clinical indicator for selecting oligo-recurrence, hepatectomy could be
an option for solitary liver metastasis from NSCLC for patients who are in good health.
Keywords: Metastatic liver tumor, Hepatectomy, Non-small cell lung cancer, Oligo-metastasis, Oligo-recurrence,
Tumor doubling time
Background
Although the recurrences that have been observed after
complete resection for non-small cell lung cancer
(NSCLC) mostly include multiple organs or sites and are
treated with systemic anticancer drugs, oligo-recurrence/
metastasis is considered a recurrent mode that could be
controlled using a definitive local therapy [1–3]. However,
selecting the appropriate patients for definitive local ther-
apy remains an intractable issue.
Since the liver is rarely observed as an oligo-recurrence/
metastasis site in patients with NSCLC [1], hepatectomies
for liver metastasis from NSCLC have rarely been
reported [4]. We encountered a patient with a rapidly
growing solitary liver mass lesion that developed after lung
resection for NSCLC and treated the patient using a
hepatectomy.
Case presentation
A 74-year-old man had undergone left lower lobec-
tomy for NSCLC (Fig. 1a). The tumor was pathologic-
ally diagnosed as squamous cell carcinoma of the
lung (1.9 cm in size) without lymph node metastasis
(TNM classification 7th edition, pT1aN0M0 and stage
IB) (Fig. 1b). He was followed up periodically, and a
computed tomography (CT) scan that was taken 1
year after the operation revealed an 8.3 cm, irregularly
shaped mass lesion in segment five of the liver
(Fig. 1c). Retrospectively, CT performed 6 months
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prior showed a 3.1 × 2.9 cm low-density lesion at the
identical site (Fig. 1d). Since 18-fluoro-2-deoxyglucose
(18F-FDG) positron emission tomography and
enhanced brain magnetic resonance imaging (MRI)
ruled out any metastatic lesions other than the one in
the liver, the patient was referred to a gastroentero-
logical surgeon. Liver MRI demonstrated a well-de-
fined mass, which was hypointense relative to the
liver parenchyma on T1-weighted images (Fig. 2a)
and hyperintense on T2-weighted images (Fig. 2b).
The hepatic mass exhibited clear hypointensity in the
late dynamic and hepatobiliary phases on ethoxyben-
zyl diethylenetriaminepentaacetic acid-MRI (Fig. 2c).
Moreover, MRI showed that the mass had increased
to 9.6 cm in diameter within a 1-month interval.
Although serum levels of carcinoembryonic antigen
(CEA; cut-off value, 3.4 ng/ml) and cytokeratin 19
fragment (CYFRA; cut-off value, 3.5 ng/ml) were both
within the normal range at the time of lung resection,
both CEA and CYFRA levels increased to 11.0 ng/ml
and 23.0 ng/ml, respectively, along with enlargement
of the hepatic mass (CEA and CYFRA levels at each
time point are indicated in Figs. 1 and 2).
Since his general condition was good and his major
organ functions were tolerable to general anesthesia,
the patient underwent right hepatectomy 14 months
after the lung resection at the primary site. Intraoper-
atively, a huge mass was detected in the right liver,
but no other metastatic sites were identified. The
postoperative course was uneventful, and the patient
was discharged on postoperative day 10.
The macroscopic examination of the cut specimen
showed an irregular, grayish mass that measured 10 ×
8 × 5.5 cm, with massive central necrosis (Fig. 3a). The
pathologic examination confirmed metastatic squamous
cell carcinoma of the lung (Fig. 3b). He did not receive
adjuvant chemotherapy and was free from recurrence
41months after the hepatectomy.
Discussion
Here, we performed a right hepatectomy for a rapidly
growing giant liver metastasis from NSCLC, and the
patient did not present recurrence 41 months after
the hepatectomy and 54 months after the lung resec-
tion. Although the liver is not a common recurrence
site [3], and reported cases of hepatectomies for liver
metastases from NSCLC are rare [4], we recom-
mended surgical resection to this patient. Since the
tumor showed substantial growth after we overlooked
the liver lesion 6 months before the initial recognition
Fig. 1 a Chest computed tomography (CT) shows 1.8-cm nodule
in the left lower lobe of the lung. b The pathological image
shows squamous cell carcinoma of the lung (hematoxylin-eosin
stain). c The abdominal CT taken 12 months after lung resection
shows an 8.3-cm mass in the right liver. d CT taken 6 months
after lung resection shows a 3.1-cm low-density lesion in the
liver. Insets in a, c, and d show serum levels of tumor markers
at the time (upper: carcinoembryonic antigen [CEA]; lower:
cytokeratin 19 fragment [CYFRA])
Fig. 2 Magnetic resonance imaging demonstrates a large mass with
hypointensity on T1-weighted images (a) and hyperintensity on T2-
weighted images (b). The tumor exhibits clear hypointensity in the
late dynamic and hepatobiliary phases (c). Inset in c shows serum
levels of tumor markers at the time (upper: carcinoembryonic
antigen [CEA]; lower: cytokeratin 19 fragment [CYFRA])
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and the new metastatic lesion did not emerge during
the 6-month interval, we considered that the liver
metastasis could be an oligo-metastasis. Retrospect-
ively, we verified whether our presumption based on
an unintentional 6-month observation was supported
by the tumor doubling time (TDT) [5]. In this case,
the TDT ranged from 38 to 50 days (Fig. 4). If the
patient had other clinically unrecognizable metastatic
lesions that were 2 mm in diameter and could grow
to a recognizable 1 cm diameter, this increase would
take 116 days, since the TDT is 50 days. Although 6
months is longer than this 116-day interval, we can
assume that a single metastatic cell from this patient
would require 30 times the TDT (30 × 50 = 1500 days)
bio-mathematically [6] to become a nodule with a
diameter of 1 cm. Thus, our presumption that this
case truly involves oligo-metastasis is not fully
supported by the TDT model. To select appropriate
patients with oligo-recurrences/metastases for defini-
tive local therapy, other clinical indicators, such as
circulating tumor cells, should be developed [7].
We reviewed hepatectomy cases from the literature
available in English and Japanese for reports of meta-
chronous liver metastases from NSCLC, excluding pa-
tients who were diagnosed with liver metastasis
concurrently with lung cancer, and found 21 cases,
including the present one (Table 1) [8–17]. Among
these patients, there is a case who is not truly
oligo-recurrence because of multiple abdominal lymph
node metastases [8]. Moreover, Nagashima et al. [17]
mentioned that they did not report two other patients
who underwent hepatectomies and did not survive.
Although it is impossible to rule out selection and
publishing biases in our review of reported cases, the
median survival time of all cases after hepatectomy is
24.3 months, and the median interval between initial
lung surgery and hepatectomy is 11 months (mean 15
months, range 1.6–48 months). The interval is not
significantly different between post-hepatectomy sur-
vival and mortality cases (mean 16.8 and 11.4 months,
Mann-Whitney U test: p = 0.40). Squamous cell
carcinoma was the dominant histologic type, and this
finding is consistent with Hishida et al.’s observation
[1], which showed that oligo-recurrence was non-
adenocarcinoma histology dominant. On survival ana-
lyses, cases of pathological stage I lung cancer showed
better post-hepatectomy prognosis than those of
pathological stage II or more (2-year survival rate
87.5% and 50.0%, respectively). Moreover, cases with
squamous cell carcinoma showed better post-hep
atectomy prognosis than those with non-squamous
histologies (2-year survival rate 87.5% and 55.6%, re-
spectively). Tumor angiogenesis varies between histo-
logic types [18], and this might affect the recurrent
mode and prognosis after definitive local therapy for
recurrence.
Conclusion
We report on a patient who underwent hepatectomy
for liver metastasis from NSCLC and remained recur-
rence free at 41 months after liver surgery. Although we
Fig. 3 a A macroscopic image of the cut specimen shows an irregular, grayish mass measuring 10.0 cm with massive central necrosis. b The
microscopic image of the liver mass shows squamous cell carcinoma
Fig. 4 Tumor doubling time (TDT) in the present case between each
time point. The indicated formula was described by Hasegawa et
al. [5]
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do not have a reliable clinical indicator for selecting
oligo-recurrent cases, hepatectomy provides an option
for patients with solitary liver metastasis from NSCLC.
Based on our review of reported cases, patients with
pathological stage I NSCLC and squamous cell carcin-
oma who undergo hepatectomies demonstrate better
post-hepatectomy prognoses.
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